Form 4: Spyre Therapeutics Director Receives Stock Option Grant

Director Michael Thomas Henderson was granted 8,026 stock options in Spyre Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Michael Thomas Henderson received a grant of 8,026 stock options for Spyre Therapeutics, Inc. (SYRE).
• The options have an exercise price of $72.51 per share.
• The grant date for these options is May 27, 2026.
• The options are scheduled to vest on the earlier of May 27, 2027, or the date of the 2027 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is subject to market volatility and the future performance of SYRE common stock.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard compensation packages for mid-cap biotechnology firms.
• The one-year vesting schedule is typical for annual director equity awards.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on May 27, 2027, or the 2027 annual meeting date.

Key Dates

Keywords

Spyre Therapeutics, SYRE, Form 4, Insider Trading, Stock Options, Director Compensation